Dissecting molecular mechanisms of resistance to Notch1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts

Valentina Agnusdei, Sonia Minuzzo, Marica Pinazza, Alessandra Gasparini, Laura Pezzè, Adriana Agnese Amaro, Lorenza Pasqualini, Paola Del Bianco, Martina Tognon, Chiara Frasson, Pietro Palumbo, Yari Ciribilli, Ulrich Pfeffer, Massimo Carella, Alberto Amadori, Stefano Indraccolo

Research output: Contribution to journalArticle

Abstract

Despite substantial progress in treatment of T-cell acute lymphoblastic leukemia, mortality remains relatively high, mainly due to primary or acquired resistance to chemotherapy. Further improvements in survival demand better understanding of T-cell acute lymphoblastic leukemia biology and development of new therapeutic strategies. The Notch pathway has been involved in the pathogenesis of this disease and various therapeutic strategies are currently under development, including selective targeting of Notch receptors by inhibitory antibodies. We previously demonstrated that the Notch1-specific neutralizing antibody OMP52M51 prolongs survival in T-cell acute lymphoblastic leukemia patient-derived xenografts bearing NOTCH1/FBW7 mutations. However, acquired resistance to OMP52M51 eventually developed and we used patient-derived xenografts models to investigate this phenomenon. Multi-level molecular characterization of T-cell acute lymphoblastic leukemia cells resistant to Notch1 blockade and serial transplantation experiments uncovered heterogeneous types of resistance, not previously reported with other Notch inhibitors. In one model, resistance appeared after 156 days of treatment, it was stable and associated with loss of Notch inhibition, reduced mutational load and acquired Notch1 mutations potentially affecting the stability of the heterodimerization domain. Conversely, in another model resistance developed after only 43 days of treatment despite persistent down-regulation of Notch signaling and it was accompanied by modulation of lipid metabolism and reduced surface expression of Notch1. Our findings shed light on heterogeneous mechanisms adopted by the tumor to evade Notch1 blockade and support clinical implementation of antibody-based target therapy for Notch-addicted tumors.

Original languageEnglish
JournalHaematologica
DOIs
Publication statusE-pub ahead of print - Aug 29 2019

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Therapeutics
Notch Receptors
Mutation
Survival
Antibodies
Neutralizing Antibodies
Lipid Metabolism
Neoplasms
Down-Regulation
Transplantation
Drug Therapy
Mortality

Cite this

Dissecting molecular mechanisms of resistance to Notch1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts. / Agnusdei, Valentina; Minuzzo, Sonia; Pinazza, Marica; Gasparini, Alessandra; Pezzè, Laura; Amaro, Adriana Agnese; Pasqualini, Lorenza; Del Bianco, Paola; Tognon, Martina; Frasson, Chiara; Palumbo, Pietro; Ciribilli, Yari; Pfeffer, Ulrich; Carella, Massimo; Amadori, Alberto; Indraccolo, Stefano.

In: Haematologica, 29.08.2019.

Research output: Contribution to journalArticle

@article{ef2563c7b76941f2b3d1cd6271ce1742,
title = "Dissecting molecular mechanisms of resistance to Notch1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts",
abstract = "Despite substantial progress in treatment of T-cell acute lymphoblastic leukemia, mortality remains relatively high, mainly due to primary or acquired resistance to chemotherapy. Further improvements in survival demand better understanding of T-cell acute lymphoblastic leukemia biology and development of new therapeutic strategies. The Notch pathway has been involved in the pathogenesis of this disease and various therapeutic strategies are currently under development, including selective targeting of Notch receptors by inhibitory antibodies. We previously demonstrated that the Notch1-specific neutralizing antibody OMP52M51 prolongs survival in T-cell acute lymphoblastic leukemia patient-derived xenografts bearing NOTCH1/FBW7 mutations. However, acquired resistance to OMP52M51 eventually developed and we used patient-derived xenografts models to investigate this phenomenon. Multi-level molecular characterization of T-cell acute lymphoblastic leukemia cells resistant to Notch1 blockade and serial transplantation experiments uncovered heterogeneous types of resistance, not previously reported with other Notch inhibitors. In one model, resistance appeared after 156 days of treatment, it was stable and associated with loss of Notch inhibition, reduced mutational load and acquired Notch1 mutations potentially affecting the stability of the heterodimerization domain. Conversely, in another model resistance developed after only 43 days of treatment despite persistent down-regulation of Notch signaling and it was accompanied by modulation of lipid metabolism and reduced surface expression of Notch1. Our findings shed light on heterogeneous mechanisms adopted by the tumor to evade Notch1 blockade and support clinical implementation of antibody-based target therapy for Notch-addicted tumors.",
author = "Valentina Agnusdei and Sonia Minuzzo and Marica Pinazza and Alessandra Gasparini and Laura Pezz{\`e} and Amaro, {Adriana Agnese} and Lorenza Pasqualini and {Del Bianco}, Paola and Martina Tognon and Chiara Frasson and Pietro Palumbo and Yari Ciribilli and Ulrich Pfeffer and Massimo Carella and Alberto Amadori and Stefano Indraccolo",
note = "Copyright {\circledC} 2019, Ferrata Storti Foundation.",
year = "2019",
month = "8",
day = "29",
doi = "10.3324/haematol.2019.217687",
language = "English",
journal = "Haematologica",
issn = "0390-6078",
publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Dissecting molecular mechanisms of resistance to Notch1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts

AU - Agnusdei, Valentina

AU - Minuzzo, Sonia

AU - Pinazza, Marica

AU - Gasparini, Alessandra

AU - Pezzè, Laura

AU - Amaro, Adriana Agnese

AU - Pasqualini, Lorenza

AU - Del Bianco, Paola

AU - Tognon, Martina

AU - Frasson, Chiara

AU - Palumbo, Pietro

AU - Ciribilli, Yari

AU - Pfeffer, Ulrich

AU - Carella, Massimo

AU - Amadori, Alberto

AU - Indraccolo, Stefano

N1 - Copyright © 2019, Ferrata Storti Foundation.

PY - 2019/8/29

Y1 - 2019/8/29

N2 - Despite substantial progress in treatment of T-cell acute lymphoblastic leukemia, mortality remains relatively high, mainly due to primary or acquired resistance to chemotherapy. Further improvements in survival demand better understanding of T-cell acute lymphoblastic leukemia biology and development of new therapeutic strategies. The Notch pathway has been involved in the pathogenesis of this disease and various therapeutic strategies are currently under development, including selective targeting of Notch receptors by inhibitory antibodies. We previously demonstrated that the Notch1-specific neutralizing antibody OMP52M51 prolongs survival in T-cell acute lymphoblastic leukemia patient-derived xenografts bearing NOTCH1/FBW7 mutations. However, acquired resistance to OMP52M51 eventually developed and we used patient-derived xenografts models to investigate this phenomenon. Multi-level molecular characterization of T-cell acute lymphoblastic leukemia cells resistant to Notch1 blockade and serial transplantation experiments uncovered heterogeneous types of resistance, not previously reported with other Notch inhibitors. In one model, resistance appeared after 156 days of treatment, it was stable and associated with loss of Notch inhibition, reduced mutational load and acquired Notch1 mutations potentially affecting the stability of the heterodimerization domain. Conversely, in another model resistance developed after only 43 days of treatment despite persistent down-regulation of Notch signaling and it was accompanied by modulation of lipid metabolism and reduced surface expression of Notch1. Our findings shed light on heterogeneous mechanisms adopted by the tumor to evade Notch1 blockade and support clinical implementation of antibody-based target therapy for Notch-addicted tumors.

AB - Despite substantial progress in treatment of T-cell acute lymphoblastic leukemia, mortality remains relatively high, mainly due to primary or acquired resistance to chemotherapy. Further improvements in survival demand better understanding of T-cell acute lymphoblastic leukemia biology and development of new therapeutic strategies. The Notch pathway has been involved in the pathogenesis of this disease and various therapeutic strategies are currently under development, including selective targeting of Notch receptors by inhibitory antibodies. We previously demonstrated that the Notch1-specific neutralizing antibody OMP52M51 prolongs survival in T-cell acute lymphoblastic leukemia patient-derived xenografts bearing NOTCH1/FBW7 mutations. However, acquired resistance to OMP52M51 eventually developed and we used patient-derived xenografts models to investigate this phenomenon. Multi-level molecular characterization of T-cell acute lymphoblastic leukemia cells resistant to Notch1 blockade and serial transplantation experiments uncovered heterogeneous types of resistance, not previously reported with other Notch inhibitors. In one model, resistance appeared after 156 days of treatment, it was stable and associated with loss of Notch inhibition, reduced mutational load and acquired Notch1 mutations potentially affecting the stability of the heterodimerization domain. Conversely, in another model resistance developed after only 43 days of treatment despite persistent down-regulation of Notch signaling and it was accompanied by modulation of lipid metabolism and reduced surface expression of Notch1. Our findings shed light on heterogeneous mechanisms adopted by the tumor to evade Notch1 blockade and support clinical implementation of antibody-based target therapy for Notch-addicted tumors.

U2 - 10.3324/haematol.2019.217687

DO - 10.3324/haematol.2019.217687

M3 - Article

C2 - 31467126

JO - Haematologica

JF - Haematologica

SN - 0390-6078

ER -